 NEW YORK, March 23, 2021 PRNewswire -- Hoth Therapeutics, Inc. NASDAQ: HOTH, a biopharmaceutical company, today announced new in vitro data demonstrating SARS-CoV-2 antiviral activity for its lead peptide candidate for HT-002, a novel therapeutic targeted for the treatment of COVID-19. The data was generated in collaboration with Dr. Michael Peters , Hoth Scientific Advisory Board Member and Professor of Chemical and Life Science Engineering at Virginia Commonwealth University. 